Funding Competition Bio-Based Industry.
As part of the CannaSyn project, the production of cannabigerol (CBG), a potentially versatile ingredient in hemp and Cannabis plant brought to…
As part of the CannaSyn project, the production of cannabigerol (CBG), a potentially versatile ingredient in hemp and Cannabis plant brought to…
The Ministry of Economic Affairs and Climate Protection is now funding eleven projects that have applied through the state competition ZukunftBIO.NRW…
The combination of Taros’ small molecule contract research and manufacturing capabilities with Welab’s longstanding expertise with drug discovery projects in a cutting-edge R&D environment will support clients in getting their
High-ranking visit to the global chemical research and development service provider Taros Chemicals at the BiomedizinZentrumDortmund at the end of 2022.
Which challenges do entrepreneurs face when setting up and establishing a CRO in Europe or Asia? This essential question will be answered by our CEO Dr. Dimitrios Tzalis in the
CARDIOMYO, the European consortium project led by ZeClinics and its partners Taros Chemicals and Amsterdam University Medical Centers, has been awarded with a budget of 2,4 million euros from the
A consortium comprising Grünenthal, Taros Chemicals and three research groups from the Institute for Neurosciences and Medicine (INM) of the Research Centre Jülich employed positron emission tomography (PET) as imaging
Cardiovascular diseases are still one of the most frequent causes of death. Since the heart muscle cannot regenerate itself, the tissue is usually remodeled leading to impaired heart function in
Taros EVP Youri R. Mesmoudi was interviewed in the current Issue of CHEManager´s Section Chemistry & Life Sciences on “From Idea to Product – the principle of an extended workbench
Due to current situation with the spread of the Sars-CoV-2 (“Coronavirus”) we want to share with you the latest information on how Taros Chemicals have prepared for both, the protection
Ahead of Oxford Global’s R&D Series Drug Discovery Virtual on 29-30 July 2020 in Berlin, Germany, Oxford Global spoke to Torsten Hoffmann of Taros Chemicals about his work in Pharmaceutical
I3-STM dealt with a new, tailor-made immunotherapeutic approach using small antibody mimetics synthesized for the therapy of triple-negative breast cancer (TNBC), which is still insufficiently treated with the classic methods.
Taros’ international and multidisciplinary team has more than 180 years of pharmaceutical R&D experience. Collectively as a team, we worked on more than 120 biomolecular…
We create performance chemicals to enhance new materials, plastics, coatings, dyes & inks, cosmetics, flavors and many more research and industrial applications…
Content
Contact
Taros Chemicals GmbH & Co. KG
Emil-Figge-Str. 76a
44227 Dortmund
GERMANY
© 2022 Taros Chemicals GmbH & Co. KG. All rights reserved.
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.
If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.
This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.
Keeping this cookie enabled helps us to improve our website.
Please enable Strictly Necessary Cookies first so that we can save your preferences!
This website uses the following additional cookies:
(List the cookies that you are using on the website here.)
Please enable Strictly Necessary Cookies first so that we can save your preferences!